Search clinical trials for: X: Orelabrutinib

Total 1214 results

Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus

Systemic Lupus Erythematosus, SLE

China
Ruijin Hospital

Recruiting

Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
InnoCare Pharma Inc.
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluating Different Doses of Orelabrutinib in MCL

Mantle Cell Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia

Primary Immune Thrombocytopenia

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia

Chronic Primary Immune Thrombocytopenia (ITP)

China
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Study to Evaluate Orelabrutinib Tablets in Subjects With Hepatic Impairment and Healthy Subject

Hepatic Impairment

China
Shandong Provincial Hospital

Recruiting

Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma

Mantle Cell Lymphoma | Diffuse Large B-cell Lymphoma | High Grade B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | B-cell NonHodgkin Lymphoma

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

An Ambispective Cohort Study of Orelabrutinib in Combination With Standard Treatment Regimen for Untreated DLBCL

Lymphoma, Large B-Cell, Diffuse Neoplasms by Histologic Type

China
Wang Xin

Recruiting

Phase IV Observational Study of Orelabrutinib in the Treatment of Chronic Lymphocytic Leukemia/Small Cell Lymphoma

CLL/SLL

China
Peking University People's Hospital

Recruiting

A Study of Orelabrutinib in CLL/SLL Patients Who Are Slowly Responding to Ibrutinib

CLL/SLL

China
Peking Union Medical College Hospital
Beijing InnoCare Pharma Tech Co., Ltd.; GCP ClinPlus Co., Ltd.

Not yet recruiting

A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder

Neuromyelitis Optica Spectrum Disorder

China
Beijing InnoCare Pharma Tech Co., Ltd.

Not yet recruiting

ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Hematologic Malignancies

China
Peking Union Medical College Hospital
Henan Cancer Hospital; Qilu Hospital of Shandong University; Beijing Tongren... and other collaborators

Recruiting

Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma

Primary Central Nervous System Lymphoma

China
Second Affiliated Hospital, School of Medicine,...
First People's Hospital of Hangzhou; First Affiliated Hospital of Zhejiang... and other collaborators

Recruiting

Orelabrutinib and Sintilimab in Relapsed or Refractory Central Nervous System Lymphoma

Primary Central Nervous System Hodgkin Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis

Relapsing Remitting Multiple Sclerosis

China, United States, Ukraine, Poland
Shandong University

Not yet recruiting

A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP

Immune Thrombocytopenia | Bruton's Tyrosine Kinase
Beijing InnoCare Pharma Tech Co., Ltd.

Completed

A Study of ICP-022 in Patients With Systemic Lupus Erythematosus (SLE)

Systemic Lupus Erythematosus

China
Peking University People's Hospital

Not yet recruiting

A Study of Orelabrutinib in Patients With ITP

Immune Thrombocytopenia

China
Sun Yat-sen University

Recruiting

Orelabrutinib Plus Rituximab Followed by Maintenance With Orelabrutinib for Relapsed and Refractory Follicular Lymphoma(RR FL)

Follicular Lymphoma | Relapsed and Refractory Follicular Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Part 1：r/r B-cell Malignancies | Part 2：B-cell Malignancies

United States, Poland, Israel, Ukraine
Fudan University

Recruiting

Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma

Helicobacter Pylori Infection | MALT Lymphoma of Stomach

China
The University of Hong Kong
London School of Hygiene and Tropical Medicine; Nagasaki University

Enrolling by invitation

Communicating Human Papillomavirus Vaccine With Japanese Parents and Caregivers With Daughters Aged 12-18

Healthy

United Kingdom
Peking University People's Hospital

Recruiting

Orelabrutinib Therapy in Patients With r/r B-cell Lymphoma Intolerant to Other Bruton Tyrosine Kinase Inhibitors

B-cell Lymphoma

China
Nanfang Hospital, Southern Medical University

Not yet recruiting

Clinical Study of Orelabrutinib Combined With BG Regimen First-line Treatment of CLL/SLL (CLL-OBG)

CLL/SLL

China
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

R-MINE+X in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma
Beijing InnoCare Pharma Tech Co., Ltd.

Recruiting

Efficacy and Safety of Orelabrutinib Plus Lenalidomide and Rituximab (R2) Compared to Placebo Plus R2 in r/r Marginal Zone Lymphoma

Relapsed/Refractory Marginal Zone Lymphoma

China
Beijing InnoCare Pharma Tech Co., Ltd.

Active, not recruiting

Evaluate the Effect of Orelabrutinib on Cardiac Repolarization in Healthy Subjects

Healthy Subject

China
Huashan Hospital

Active, not recruiting

A Retrospective Study of Newly-diagnosed PCNSL Treated With a Methotrexate (MTX) and Orelabrutinib-based Regimen

Primary Central Nervous System Lymphoma

China
Shandong Cancer Hospital and Institute
The First Affiliated Hospital of Nanchang University

Recruiting

A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With Double Expression Diffuse Large B-cell Lymphoma

The First Affiliated Hospital of Nanchang University

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Patient-Specific Computational Walking Models in Improving Surgical and Rehabilitation Treatment in Patients With Pelvic Sarcomas

Pelvic Sarcoma

United States
Mansoura University

Completed

A 2-year Clinical Impact of Bulk-fill Low-viscosity Resin Composite Liners in Class II Restorations.

Dental Caries Class II

Egypt
Sun Yat-sen University

Not yet recruiting

Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma (O-Gemox)

DLBCL

China
Mirati Therapeutics Inc.

Completed

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Lymphoma

United States, Canada
Catholic University of the Sacred Heart
SOFAR S.p.A.

Unknown

Teleassisted Surgery for Gynecological Disease in Obese Patients - OB-ALFX (OB-ALFX)

Benign, Premalignant and Malignant Gynecological Disease Confined to the Pelvis

Italy
Azienda Ospedaliera San Giovanni Battista
FondazioneCRT

Completed

The RAD-HOME Project: a Pilot Study of Domiciliary Teleradiology (RHP)

Pneumonia | Osteomyelitis | Fractures | Acute Congestive Heart Failure | Exacerbation of COPD

Italy
Celltrion

Active, not recruiting

Study to Evaluate and Compare the Efficacy and Safety of AZM and AML Combined and Alone in Mild-to-moderate Essential Hypertensive Subjects

Essential Hypertension

Korea, Republic of
Celularity Incorporated

Completed

Study of Human Placenta-derived Cells (PDA002) to Evaluate the Safety and Effectiveness in Subjects With PAD and DFU

Diabetic Foot | Peripheral Arterial Disease

United States
University Hospital, Ghent

Completed

Comparison of Acute Toxicity and Cost Between Whole Breast Irradiation With Sequential Boost and Simultaneous Integrated Boost After Breast Conserving Surgery. (SeqB vs SIB)

Radiotherapy After Breast Conserving Surgery

Belgium
Carina Biotech Limited

Recruiting

A Study of CNA3103 (LGR5-targeted, Autologous CAR-T Cells) Administered to Subjects With Metastatic Colorectal Cancer

Colorectal Cancer Metastatic

Australia
On-X Life Technologies, Inc.

Terminated

On-X Heart Valve - 17mm Aortic and 23mm Mitral

Heart Valve Disease

United States, Puerto Rico, Spain
The Netherlands Cancer Institute

Terminated

Comparing Two Palliative Schemes of Radiotherapy for Head and Neck Cancer (COOPERATION)

Head and Neck Neoplasms

Netherlands
National Cancer Institute (NCI)

Active, not recruiting

Screening for Lung Cancer in Older Patients (PLCO Screening Trial)

Lung Carcinoma

United States
Hospices Civils de Lyon

Completed

Stereotactic Radiotherapy for Renal Cancers (RSR-1)

Renal Cancer

France
Odense University Hospital

Active, not recruiting

Coagulation System In STereotactic Radiotherapy Of NSCLC (CISTRON)

NSCLC | Lung Cancer | Thromboembolism | Radiotherapy; Complications

Denmark
InnoCare Pharma Inc.

Not yet recruiting

A Global Phase 3 Study of Orelabrutinib+BR vs.BR in Pts With TN MCL

Mantle Cell Lymphoma
Fujifilm Medical Systems USA, Inc.

Terminated

Pilot Study Comparing Diagnostic Imaging Versus Tomosynthesis in Detection of Hip, Wrist or Tibia Injury (TOMO)

Tibial Fracture | Wrist Injury | Hip Injury

United States
Bausch & Lomb Incorporated

Completed

Evaluation of BOL-303242-X Versus Vehicle for the Treatment of Inflammation Following Cataract Surgery

Inflammation | Cataract

United States
Medtronic Spine LLC

Withdrawn

Effects of X-STOP® Versus Laminectomy Study (EXELS)

Lumbar Spinal Stenosis
Celularity Incorporated

Terminated

Efficacy and Safety of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With and Without Peripheral Arterial Disease

Diabetic Foot | Peripheral Arterial Disease

United States
Microvention-Terumo, Inc.

Recruiting

MicroVention, Inc. Flow Re-Direction Endoluminal Device X (FRED™ X™) Post-Approval Study

Intracranial Aneurysm

United States

Search clinical trials for: X: Orelabrutinib

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Montenegro

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations